# Clinical Study on the Immunomodulatory Effect of Eprolidone on Patients With Chronic Heart Failure

> **NCT05924958** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Cheng LuFeng,Principal Investigator** · enrollment: 800 (estimated)

## Conditions studied

- Chronic Heart Failure Patients

## Interventions

- **DRUG:** Eprolidone

## Key facts

- **NCT ID:** NCT05924958
- **Lead sponsor:** Cheng LuFeng,Principal Investigator
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05924958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05924958, "Clinical Study on the Immunomodulatory Effect of Eprolidone on Patients With Chronic Heart Failure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05924958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*